Refractory Lymphomas Not Yet Recruiting Phase 2 Trials for Ibrutinib (DB09053)

Also known as: Refractory Lymphoma

IndicationStatusPhase
DBCOND0042145 (Refractory Lymphomas)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04994626Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior TherapiesTreatment